Capricor Therapeutics Inc to Discuss the Top-Line Results of the HOPE-2 Study - Call Transcript

May 13, 2020 / 12:00PM GMT
Operator

Thank you for standing by. This is the conference operator. Welcome to the Capricor Therapeutics HOPE-2 top-line 12-month data call. As a reminder, all participants are in listen only mode, and the conference is being recorded. (Operator Instructions)

I would now like to turn the conference over to AJ Bergmann. Please go ahead.

AJ Bergmann - Capricor Therapeutics, Inc. - CFO

Thank you, and good morning, everyone. Before we start, I would like to state that we will be making certain forward-looking statements during today's presentation.

These statements may include statements among other things regarding the efficacy, safety, and intended utilization of our product candidates; our future research and development plans, including anticipated conduct and timing and preclinical and clinical studies; our plans to present or report additional data; our plans regarding regulatory filings, potential regulatory developments, involving our product candidates; and our possible uses of existing cash and investment resources.

These forward

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot